MKI67 and lung cancer: Previous work indicates increases in metabolic pathways in the airways of subjects with dysplastic lesions14, in PMLs adjacent to LUSC tumor24, and in smokers at high-risk for lung cancer25 as well as increases in proliferation (via Ki67 levels, as mentioned above) that have been utilized as an endpoint in lung cancer chemoprevention26,27.